Latest News
CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer
24 July 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Trodelvy (sacit...
Active Biotech doses first patient in amended tasquinimod myelofibrosis study
24 July 2026 - Swedish biotechnology company Active Biotech AB (STO:ACTI) announced on Friday that the first patient has been dosed in the amended Phase Ib/II clinical study of tasquinimod in patients with myelofibrosis who are refractory to or ineli...
Ipsen's Phase III BOLD trial misses primary endpoint in biliary atresia
24 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) disclosed on Friday that its Phase III BOLD trial evaluating Bylvay (odevixibat) versus placebo in patients with biliary atresia who had undergone Kasai hepatoport...
Sanofi ends atopic dermatitis development for amlitelimab
24 July 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Friday that it will discontinue the clinical development of amlitelimab, an OX40-ligand monoclonal antibody, for moderate-to-severe atopic dermatitis (AD) ...
ArkBio completes Australian dosing in Phase I trial of influenza AFC drug AK0406
24 July 2026 - Chinese biotechnology company Shanghai Ark Biopharmaceutical Co Ltd ('ArkBio') announced on Thursday that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiv...